1	
2	Evaluation of long-term sequelae by cardiopulmonary exercise testing
3	12 months after hospitalization for critical COVID-19
4	Sofia Noureddine ^{1*} , Pauline Roux-Claudé ^{1*} , Lucie Laurent ¹ , Ophélie Ritter ¹ , Pauline Dolla ¹ ,
5	Sinan Karaer ¹ , Frédéric Claudé ¹ , Guillaume Eberst ^{1,2} , Virginie Westeel ^{1,2} , Cindy Barnig ^{1,3}
6	
7	
8	¹ Department of Chest Disease, University Hospital Besançon, France
9	² Methodology and Quality of Life in Oncology Unit, University Hospital, Besançon, France
10	and UMR 1098, University of Franche-Comté, Besançon, France
11	³ University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions
12	Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, LabEx LipSTIC, F-25000
13	Besançon, France
14	
15	*Shared co-first authorship
16	Address correspondence to:
17	Cindy Barnig
18	Department of Chest Disease,
19	University Hospital Besançon,
20	F-25000 Besançon, France
21	Tel: +33 3 81 66 88 02
22	e-mail : cindy.barnig@univ-fcomte.fr
23	
24	
25	
26	
27	

28 Abstract

Background: Cardiopulmonary exercise testing (CPET) is an important clinical tool that provides a global assessment of the respiratory, circulatory and metabolic responses to exercise which are not adequately reflected through the measurement of individual organ system function at rest. In the context of critical COVID-19, CPET is an ideal approach for assessing long term sequalae.

Methods: In this prospective single-center study, we performed CPET in 60 patients, 12 months after a critical COVID-19 infection that required intensive care unit (ICU) treatment.

Lung function at rest and chest computed tomography (CT) scan were also performed.

37 **Results:** Twelve months after severe COVID-19 pneumonia, the majority of the patients had a peak O_2 uptake (V' O_2) considered within normal limits. However, length of ICU stay 38 39 remained an independent predictor of V'O₂. Surprisingly, more than half of the patients with a normal peak predicted VO_2 showed ventilatory inefficiency during exercise (high 40 VE/VCO₂ ratio and high VE/VCO₂ slope) with increased physiological dead space (VD/Vt) 41 42 and low end-tidal CO_2 partial pressure (PETCO₂) values. This impairment was even more 43 pronounced in patients with persistent dyspnea. Notably, peak VD/Vt values were positively correlated with peak D-Dimer plasma concentrations from blood samples 44 45 collected during ICU stay.

Conclusions: Even if reduced exercise capacity was rare 12 months after critical COVID 19, more than half of the patients with normal exercise capacity showed ventilatory
 inefficiency.

49

50

52 Background

In December 2019, Wuhan city identified a new type of coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that rapidly spread all over the world and caused an immense global health crisis. Most patients presented mild to moderate respiratory disease, experiencing cough, fever, headache, myalgia, diarrhea and anosmia. However, around 3–20% of people with SARS-CoV-2 required hospitalization and a considerable subset needed intensive care because of respiratory failure with severe hypoxemia and bilateral radiographic opacities [1].

50 Studies found that most SARS-CoV-2 survivors, even those who were critically ill 51 during hospital stay, have normal pulmonary function tests within 12 months after 52 symptom onset [2]. Nevertheless, more than half of the patients who recover from 53 Coronavirus disease 2019 (COVID-19) complain of long-term persistent dyspnea [3].

Cardiopulmonary exercise testing (CPET) is an important clinical tool that provides 64 a global assessment of the respiratory, circulatory and metabolic responses to exercise 65 66 which are not adequately reflected through the measurement of individual organ system 67 function at rest [4]. In the context of COVID-19, CPET is an ideal approach for unmasking 68 functional anomalies and long term segualae. To date, only a few studies have 69 investigated the exercise capacity in patients who have recovered from COVID-19. 70 Assessment in the short-term post-COVID period revealed mostly a mild decrease in peak 71 O_2 uptake (V' O_2) and a low anaerobic threshold, without cardiac impairment or ventilatory 72 limitation, suggestive of physical deconditioning [5, 6]. However, there is currently limited 73 data on long term functional capacities in patients after COVID-19, especially after critical infection. 74

The aim of our study was to evaluate cardiopulmonary exercise capacities in a prospective cohort of patients that required critical care management during the first wave

of COVID-19, 12 months after symptom onset.

78 Methods

79 Study design and subjects

80 This was a prospective single-center observational cohort study. All patients who 81 were admitted between April to June 2020 to any of the intensive care units (ICU) of the 82 University Hospital of Besançon (France) for a COVID-19 infection were contacted upon 83 hospital discharge and invited to participate in the trial. Patients were eligible if they were >18 and < 80 years old and had initially confirmed SARS-CoV-2 infection by quantitative 84 85 RT-PCR on nasal swabs or bronchoalveolar lavage. Patients were excluded if they were known to have prior chronic respiratory insufficiency, if they had a significant psychiatric 86 87 pathology, or if they had a life expectancy estimated at less than one year. The protocol was approved by the ethics committee (Comité de Protection des Personnes (CPP) 88 89 Grand-Est Ref 21 04 11) and written informed consent was obtained from all patients at 90 the time of enrollment.

91 The study consisted of a follow-up at 3, 6 and 12 months after symptom onset 92 (NCT04519320). From 149 patients that were initially admitted to intensive care with a 93 diagnosis of SARS-CoV-2, a total of 85 patients were included in the cohort study (suppl Figure). Seventy-three patients (86%) completed the 12 months visit. A clinical evaluation, 94 95 lung function tests, chest computed tomography (CT) and CPET were carried out on the 96 same day. A total of 64 patients performed CPET (2 patients declined to perform CPET, 2 had no negative RT-PCR control for SARS-CoV-2 and 6 had contraindications for 97 performing CPET (pericardial effusion, acid-base disorders, orthopedic pathology and 98 99 recent head trauma)). Four patients were excluded from the final analysis, 3 because of 100 submaximal efforts and 1 patient that had presented severe arrhythmia during the test 101 leading to an early exercise termination.

102

103

104 **Pulmonary function tests**

Pulmonary function tests were realized in all the patients and included spirometry, measurement of lung volumes by plethysmography and single-breath determination of diffusion capacity of the lung for carbon monoxide (D_{LCO}) (Platinum Elite, MGC Diagnostic Coroporation). Predicted normal values were derived from the reference values in accordance with current recommendations [7, 8]. The modified Medical Research Council (mMRC) dyspnea scale (0 to 4) was used to rate chronic dyspnea [9]. Participants were categorized as having dyspnea (mMRC \geq 1) or not (mMRC = 0).

112 **CT image acquisition and analysis**

113 Chest CT scans were acquired in the supine position at full inspiration without 114 contrast medium (Revolution CT; GE Healthcare, Milwaukee, WI, USA). CT images were assessed by two readers blinded to clinical data that evaluated the presence and extent of 115 116 around-alass opacities (GGOs), reticulations, bronchiectasis, emphysema and honevcombing as defined by the glossary of terms of the Fleischner Society [10]. 117

118 Cardiopulmonary exercise test

119 Symptom-limited incremental CPET was performed according to the ERS 120 guidelines on an electronically braked cycle ergometer (Ergometrics 900; Ergoline; Bitz, 121 Germany) [11].

After a steady-state resting period, a 3 min warm-up was conducted at about 20% of individually estimated maximal workload. A progressive increase in workload was then applied every minute (10 to 20 W/min) depending on the patient's physical condition, medical history and according to a total exercise time between 8 and 12 minutes. Tests

were terminated at the point of symptom limitation (peak exercise) or in the presence of electrocardiographic changes. Subjects rated the magnitude of their perceived breathing and leg discomfort by pointing to a number on the 10-point Borg scale [12]. Oxygen saturation with pulse oximetry, heart rate (HR) and 12-lead electrocardiogram (ECG) and non-invasive blood pressure measurements were monitored throughout exercise.

131 Breath-by-breath gas exchange values were measured using a Masterscreen CPX 132 metabolic cart (MGC-CPX System; MGC Diagnostics Corporation) and were expressed as 30 s averages, according to recommended guidelines. Minute ventilation (V'E), oxygen 133 134 uptake (V'O₂), carbon dioxide production (V'CO₂), end-tidal partial pressure of carbon 135 dioxide (PetCO₂), tidal volume (Vt) and breathing rate were recorded. Oxygen pulse $(V'O_2/heart rate)$, ventilatory equivalent for oxygen uptake $(V'E/V'O_2)$ and ventilatory 136 137 equivalent for carbon dioxide production (V'E/V'CO₂) were calculated. The respiratory exchange ratio (RER) was defined as $V'CO_2/V'O_2$. The anaerobic threshold (AT) was 138 determined by both ventilatory equivalents and V-slope methods. V'E/V'CO₂ slope was 139 calculated from rest to peak exercise. 140

141 Blood samples were drawn from the arterialized earlobe and measurements of 142 partial pressure of oxygen (PaO₂) and carbon dioxide (CO₂) were performed at rest, at 143 anaerobic threshold (AT) and at peak exercise. Lactatemia was determined at rest, at AT, 144 at maximal exercise and 5 min of recovery time. Breathing reserve (BR) % was calculated as BR = (predicted maximum voluntary minute ventilation [MMV] – peak VE)/MMV x 100, 145 with predicted MMV = FEV1 \times 40. Peak heart rate (HR) was expressed as a percentage of 146 maximum predicted HR, calculated as HR max = $210 - (0.65 \times age)$. Physiological dead 147 148 space (VD/Vt) was calculated according to Bohr's equation corrected for the additional instrument dead space: $VD/Vt = (PaCO_2 - PetCO_2 mean)/PaCO_2 - (VD [machine]/Vt)$. 149

Tests were considered maximal if a plateau of the V'O₂ > 60 seconds was obtained (variation of V'O₂ <150 mL between 2 increments), RER > 1.1, a perceived exertion >7 on

the Borg scale, peak HR > 100% of predicted, breathing reserve <15% and/or important
 metabolic acidosis.

Normal predicted values for $V'O_2$ were calculated according to the reference equation of Wassermann [13]. A reduced peak exercise capacity was defined by a peak V'O₂ < 85% of predicted [4].

157 Statistical analyses

Statistical analysis was performed using GraphPad Prism version 9.0 (GraphPad 158 159 Software Inc., San Diego, CA, USA). Normal distribution of quantitative variables was 160 tested by the Kolmogorov-Smirnov test. Descriptive statistics are presented as mean ± standard deviation (SD), median (25th to 75th percentile), or number (%), as appropriate. 161 162 Student's T or Mann–Whitney U-test tests were computed to assess statistical differences 163 between groups for normal or non-normal quantitative variables, respectively. Categorical variables were analyzed by Fisher's exact test when appropriate. Correlations were 164 165 examined by Spearman rank test or Pearson test. Multiple linear regression was applied 166 for peak V'O₂ (ml/kg/min) as dependent variable, using a stepwise approach of potential 167 determinants that showed significant associations in previous univariate analysis. Age, sex 168 and body mass index (BMI) were included in the final multivariable model. The reported p 169 values were two-sided, with a significance level set at p<0.05.

170

171

172

174

175

176 **Results**

177 Baseline characteristics of the study population

The demographics, comorbidities and ICU treatments of patients at inclusion are 178 179 summarized in Table 1. The mean age was 64.6 years (± 9.6), 78% were male. All patients were initially admitted in an intensive care unit (ICU) and were treated according 180 181 to local standards at that time. The majority of the patients fulfilled criteria for initial ARDS 182 according to the Berlin definition [14], 90% were intubated, 45% received steroids and more than 90% received early anticoagulant therapy. A pulmonary embolism was 183 diagnosed in 27% of the patients during their stay. Peak values during ICU stay for main 184 185 blood laboratory findings are shown in Table 1. All patients included in the study had early 186 rehabilitation during their hospital stay. More than half of the patients (65%) were further 187 referred to a pulmonary rehabilitation center and most of the other patients had regular 188 home physiotherapy sessions after their hospital discharge.

189 Characteristics of the study population at 12 months follow-up

The clinical, pulmonary function tests and imaging characteristics of the patients at 190 191 12 months follow-up are summarized in Table 2. Persistent dyspnea was reported by half of the patients (50%) (mMRC scale \geq 1). Only a minority of patients had functional 192 193 pulmonary impairment at rest. Two patients showed a mild restrictive ventilatory pattern, and 4 patients had airflow obstruction, three of them had a previous diagnosis of COPD. 194 195 Mildly impaired DLCO, defined as Z-score DLCO < -1.64, was present in 6 patients (10%), 196 4 were already diagnosed with COPD before SARS-CoV2 infection. High resolution 197 computed tomography (HRCT) of the chest showed pulmonary abnormalities in 50

198 patients (84%). Cardiac evaluation at rest was only proposed to patients that had 199 presented pulmonary embolism during their hospital stay. In these patients, transthoracic 200 echocardiography was within normal limits with no signs of pulmonary hypertension.

201

Cardiopulmonary exercise test (CPET) results at 12 months follow-up

202 Adequate exercise test efforts were obtained in all the patients analyzed. Table 3 203 summarizes the main exercise parameters of the study cohort at the anaerobic threshold 204 (AT) and at peak. Most of the patients had an adequate V'O₂ at AT (median predicted 205 64.8% [57.2-70.9]). The median peak predicted V'O₂ was 98 % [87.2-106.3]) (mean peak 206 VO_2 21.7 ± 5.2 mL/min/Kg). Reasons for stopping exercise were leg discomfort in 55% of patients, breathing discomfort in 36.6% patients and both in 5% patients. 207

208 Circulatory parameters revealed a mean peak predicted oxygen pulse at 103.7 % (± 209 19.9). Only 8 patients had a mildly decreased O_2 pulse, 3 of them were under 210 betablockers. The mean peak predicted heart rate was 96.6 % (± 12.7), and the median 211 $HR/V'O_2$ slope was in the limit of normal at 41.9 (33.6-48.7).

212 Mean respiratory equivalents at peak were slightly elevated compared to expected 213 values (V'E/V'O₂ ratio at 42.7 [\pm 6.6] and V'E/V'CO₂ ratio at 37.5 [34-42]) and the mean 214 V'E/V'CO₂ slope from rest to peak was also slightly skewed to increased values compared 215 to expected values (37.2 ± 6.7) [15]. There was also a trend to a widened median alveolar-216 arterial O_2 pressure difference at peak (35.2 mmHg [31.2-44.8]).

217

Predictors of peak oxygen uptake

218 We next examined the relationship between peak V'O₂ (ml/min/kg) and variables of 219 interests. Univariate analysis revealed that peak V'O2 was strongly correlated to the 6-220 minute walk test (MWT) distance recorded at 12 months (Figure 1a). As expected, 221 absolute values of lung function test parameters at 12 months (FEV₁, VC and D_{LCO}) were 222 significantly associated to peak $V'O_2$ (suppl Table 1).

Among variables recorded during the management of the acute COVID-19 infection, length of ICU stay showed the most significant correlation with peak V'O₂ (Figure 1b). Simplified acute physiology score (SAPS II) and length of curarization had a weaker correlation with peak V'O₂ (suppl Table 1).

In a multiple linear regression analysis, the length of ICU stay remained an independent predictor of V'O₂ and combined to age, sex, and BMI explained 57% of the variance of V'O₂ peak at 12 months (Table 4).

230 Comparison of patients with reduced and normal exercise capacity

231 Twelve patients (20%) had reduced peak exercise capacity (V'O₂ <85% of predicted) (Table 5). The median peak predicted V'O₂ (82% [73.9-83.9]) and workload 232 233 (85.7 % [80.1-96.9]) were only mildly decreased. When compared to patient with 234 preserved peak exercise capacity, patients with reduced capacity had a significantly higher 235 BMI $(33.4 \pm 6.2 \text{ vs} 30.1 \pm 4.5, p=0.04)$ and a significantly longer ICU stay $(29.7 \pm 13.1 \text{ vs})$ 236 19.1 \pm 11.3 p=0.006). No significant differences were observed between both groups 237 regarding age, other prior comorbidities, pulmonary embolism during ICU stay and 238 respiratory rehabilitation. No significant differences were observed for CT scan 239 abnormalities. However, patients with a reduced exercise capacity had a significantly lower 240 % predicted FEV1 (97.4 ± 16.9 vs 110.8 ± 19.7; p=0.03), FVC (97.5 ± 17.8 vs 110.8 ± 16.9, p=0.01) and a lower % predicted D_{LCO} (91.3 (65.6-98.1) vs 103 (92.3-114.2); 241 242 p=0.01). Assessment of each individual with limited peak exercise capacity revealed that 243 the primary limitation was ventilatory limitation in 6 patients (50%). Among patients with 244 ventilatory impairment, 5 of them were former smokers and had prior COPD and/or lung 245 emphysema on chest CT. Physical deconditioning was observed for the 6 (50%) others 246 patients.

In the group of patients having an exercise capacity considered within normal limits,

the median peak predicted V'O₂ was 101.6 % [94.8-107.5] (mean of 23.0 ml/kg/min [±4.7]) (Table 5). The main reasons for termination were leg discomfort in 52.1% of patients and dyspnea in 37.5%. Despite having a normal exercise capacity, it was worth noting that patients had increased mean ventilatory equivalents for CO₂ with a mean peak V'E/V'CO₂ at 37.5 (34-41) and a mean V'E/V'CO₂ slope from rest to peak at 37.2 [±6.6]. The median median alveolar-arterial O₂ pressure difference at peak appeared also widened (34.7 mmHg [31.7-43.9]).

255 Ventilatory efficiency parameters in patients with normal exercise capacity

As we observed that a majority of patients with normal exercise capacity showed elevated mean ventilatory equivalents for CO_2 during exercise, we next focused on the evolution of ventilatory efficiency parameters in this group.

259 It was worth noting that at AT, 18 of those 48 patients (37.5%) had a V'E/V'CO₂ 260 ratio > 35 and 7 patients (14.6%) had even a V'E/V'CO₂ ratio > 40. At peak exercise, 56.2% (n=27) of patients had a V'E/V'CO₂ slope > 35 and 41.7% (n=20) had a V'E/V'CO₂ 261 262 slope > 40. Anarchical evolution of tidal volume was not observed. In contrast, elevated 263 ventilatory equivalents for CO₂ were associated with abnormal dead space ventilation. 264 Indeed, an abnormal increase of the physiological dead space from AT to peak was 265 observed in 68.1% (n=32) of the patients with a median VD/Vt of 0.27 (0.21-0.32) at AT 266 and 0.29 (0.25-0.34) at peak (Figure 2a). Moreover, the median peak alveolar-arterial 267 gradient for O₂ was abnormally elevated (35.2 mmHg [31.2-44.8]) with 48.9 % of patients (n=23) having a P(A-a) \geq 35 mmHg (Figure 2b). PetCO₂ at peak was significantly lower in 268 subjects with an abnormal increase of VD/Vt (p=0.001) (Figure 2c). 269

Univariate analysis revealed that dead space at peak (VD/Vt) was associated with parameters related to pulmonary exchange capacity at rest (pulmonary diffusing capacity) and during exercise (V'E/V'CO₂ ratio and slope, PetCO₂, pO₂ and alveolar-arterial gradient (Table 6). Notably, dead space at peak was positively correlated to D-Dimer plasma

concentration from blood samples collected during ICU stay. Reanalysis after excluding
 patients with pulmonary embolism during ICU stay did not alter this correlation.

Interestingly, patients with persistent dyspnea (n=23) had a significantly higher mean peak dead space (0.32 \pm 0.07 vs 0.28 \pm 0.06; p=0.04) and a higher widening of their mean peak alveolar-arterial gradient (40.9 \pm 9.8 vs 34.2 \pm 5.9; p=0.006) (Suppl Table 2). There was no significant difference for the mean peak VE/VCO₂ ratio and the mean VE/VCO₂ slope. Performance and circulatory parameters during exercise were also similar between both groups. As expected, breathlessness was the predominant symptom that resulted in test termination in patients with persistent dyspnea. Patients with persistent dyspnea were slightly older. No differences were observed for any other parameters recorded during initial hospitalization including the presence of pulmonary embolism between patients with and without persistent dyspnea. Lung function at rest was also similar at 12 months between both groups (Suppl Table 2).

298			
299			
300			
301			
302			

303

304

305 Discussion

This prospective study assessed cardiopulmonary exercise performance in 60 patients, 12 months after a critical COVID-19 infection during the first wave that required initial ICU management. The patients of our cohort presented well-established risk factors for severe COVID-19 such as advanced age, a predominance of male sex and a high BMI [16]. As expected, hypertension and dyslipidemia were the most frequent chronic comorbidities.

312 Despite the severity of the initial clinical presentation, exercise capacity assessed 313 by CPET were within normal limits in most of the patients 12 months after the acute 314 infection. Impairment was predominantly related to persistent deconditioning or prior respiratory co-morbidities. These results confirm previous studies assessing exercise 315 capacity by CPET 3 to 6 months after hospital release and reporting that remaining 316 exercise limitation after COVID-19 is primarily related to physical deconditioning rather 317 318 than to physiological impairment [5, 6, 17, 18]. Thus, recovery of physical capacities after a 319 critical COVID-19 infection appears better than in patients with other ARDS etiologies [19, 20]. 320

In our study, 12 months after the acute infection, the length of ICU stay was still an independent predictor of peak $V'O_2$, including the patients that had recovered a peak $V'O_2$ considered within normal limits. Even if other studies have already reported associations

between length of ICU stay after COVID-19 and peak V' O_2 [21, 22], we were surprised that this association remained still true several months after hospital release. This was even more unexpected as all our patients had received early physiotherapy management in the acute hospital setting followed by either inpatient rehabilitation or extensive physiotherapy for several weeks at home for most of them.

Another intriguing observation in our study was that many patients having a peak V'O₂ within normal limits and normal rest lung function, showed ventilatory inefficiency during exercise, with increased V'E/V'CO₂ ratios at AT and at peak associated with an increased V'E/V'CO₂ slope. Ventilatory inefficiency after acute COVID-19 has already been reported but mainly attributed to dysfunctional breathing with inappropriate hyperventilation suggestive of post-traumatic syndrome [23]. In contrast to our study, these studies enrolled predominantly patients having had mild COVID-19 [21, 24-26].

336 In our patients, there was no evidence of exaggerated hyperventilatory response. 337 Indeed, we did not see abnormal respiratory alkalosis, nor anarchical evolution of tidal 338 volume. However, ventilatory inefficiency was associated in our study with increased 339 physiological dead space ventilation. Indeed, we observed that nearly two-thirds of the 340 patients with a normal peak predicted V'O₂ exhibited an increase of the VD/Vt ratio 341 between AT and peak exercise. Ventilatory inefficiency without hyperventilation syndrome 342 has been suggested by other groups but these studies included patients with a range of 343 disease severity combining data from outpatients, hospitalized patients, and those who 344 had required admission to the ICU [22, 27]. Of interest, Ambrosino et al. identified in a 345 study that included mostly severe-to-critical COVID-19 patients without any prior history of 346 cardiovascular or pulmonary disease shortly after hospital release, higher VE/VCO₂ ratios 347 and VE/VCO_2 slopes and a lower VD/Vt decrease among patients with reduced exercise 348 capacity [28].

349

In healthy individuals, VD/Vt decreases usually during exercise as Vt increases

350 several folds and to a much greater extent than the small increase in VD [29]. An increase 351 of the physiological dead space ventilation during exercise is usually considered as 352 abnormal and may suggest the presence of several cardiac and pulmonary disorders. 353 However, increasing VD/VT during exercise is mostly sensitive for pulmonary vascular 354 disease [30-32]. As in our study the majority of patients with normal exercise capacity had 355 normal rest pulmonary function and no cardiovascular abnormalities, the increase of 356 physiological dead space ventilation associated to a low peak PetCO₂ may point to 357 pulmonary vascular disease.

358 It is now apparent that SARS-CoV-2 infection induces endothelial cell dysfunction 359 with systemic inflammatory response resulting in a prothrombotic state manifesting 360 especially with microthrombosis [1]. Notably, in our study, peak VD/Vt values at 12 361 months were positively correlated to peak D-Dimers plasma concentrations from blood 362 samples collected during ICU stay. D-Dimers are a strong biomarker for hypercoagulability 363 and thrombotic events and can be linked to endothelial dysfunction reported during acute 364 COVID-19 [33, 34]. Therefore, the observed ventilatory inefficiency in our patients may 365 point to infra-clinical pulmonary vasculopathy sequelae due to lung micro-thrombotic events during acute SARS-CoV-2 infection. In a study aiming to quantify endothelial 366 367 alterations in 23 patients with moderate to critical COVID-19, sublingual video microscopy 368 confirmed microcirculatory alterations that were closely associated with D-Dimer levels 369 [35]. More recently, in a cohort of severe-to-critical COVID-19 patients, Ambrosino et al. 370 showed that persistent endothelial dysfunction explored by ultrasound assessment of 371 endothelium-dependent flow-mediated dilation (FMD) was correlated to ventilatory 372 inefficiency parameters during CPET in a subgroup of patients [28].

Half of our patients, including those who had an exercise capacity within normal limits, still complained of persistent dyspnea. A recent study evaluating the health-related quality of life and persistent symptoms in critically ill COVID-19 patients at twelve months

identified a similar proportion with 58.4% of patients with persistent mild dyspnea that was weakly correlated with both DLCO and length of invasive mechanical ventilation [36]. In our study, we found no clear association between dyspnea, length of ICU stay, effort capacity or rest lung function parameters. However, patients with persistent dyspnea had significantly higher mean peak dead space associated to a higher widening of their mean peak alveolar-arterial gradient during exercise.

382 Some potential limitations of our study should be noted. Our study was conducted 383 in a single center. There was also a missing baseline assessment of cardiopulmonary 384 function at rest before SARS-CoV-2 infection in our patients. Even if nearly all the patients 385 with normal exercise capacity and ventilatory inefficiency at exercise had spirometry and 386 predicted DLCO within normal limits, it would have been interesting to compare the results 387 with matched controls. Indeed, more than half of our study cohort were smokers or former 388 smokers. Moreover, we were not able to measure the diffusing capacities of the lung for 389 nitric oxide (NO) which combined to D_{LCO} would have been useful to evaluate more 390 precisely the pulmonary vascular implication. Finally, all patients of our cohort were treated 391 according to local standards at the time of the first wave of COVID-19. Consequently, only 392 45% of them received corticosteroids but notably all of the patients were precociously 393 anticoagulated during their ICU stay.

394

395

396

397

398

399

Conclusion

In the current study we report that 12 months after critical COVID-19 most of the patients had a peak V'O₂ considered within normal limits. The length of the ICU stay remained a significant predictor of peak V'O₂ and therefore prolonged cardiopulmonary rehabilitation and exercise activity should be encouraged in this population. Notably, more than half of the patients who had a normal exercise capacity were still complaining of persistent dyspnea and two-thirds showed abnormal ventilatory efficiency during exercise suggestive of pulmonary vasculopathy. These findings may raise the question of a prolonged antithrombotic therapy in the management of critical post-COVID-19. Further studies, based on invasive hemodynamic measurements during exercise are required to clarify our observations.

427			
428			
429			
430			
431			
432			
433			
434			

Table 1. Baseline characteristics of the study population.

	<i>n</i> = 60
Age (years)	64.6 ± 9.6
Male	47 (78%)
BMI (kg/m²)	30.7 ± 5
Smoking status	
Active smoker	1 (1.7%)
Former smoker	33 (55%)
Never smoker	26 (43.3%)
Comorbidities before SARS-CoV-2 infection	
Obesity (BMI> 30)	33 (55%)
Cardiovascular	
Ischemic heart disease	5 (8.3%)
Hypertension	28 (46.7%)
Dyslipidemia	21 (35%)
Diabetes	15 (25%)
Respiratory diseases	
COPD	5 (8.3%)
Asthma	6 (10%)
Sleep apnea	12 (20%)

Deep vein thrombosis	3 (5%)
Pulmonary embolism	0 (0.0%)
Initial hospital management	
Intensive care unit	
Length of ICU stay (days)	21.2 ± 12.4
ARDS	54 (90 %)
Endotracheal intubation with mechanical ventilation	54 (90 %)
Neuromuscular blocking agents	53 (89.8%)*
High-dose steroids	27 (45%)
Anticoagulant therapy	55 (91.7%)
Prone position	47 (79.7%)*
Pulmonary embolism	16 (26.7%)
DDimers (ng/ml)	2760 (1601-4507)**
Fibrinogen (g/L)	5.06 ± 1.16
Creatinine (mg/dl)	87.0 (71-117)
CRP (mg/ml)	199.8 ± 94.6
Total WBC count (10 ⁹ /L)	5.4 ± 1.3
Pulmonology unit stay (days)	48.9 ± 36.5
Total length of stay (days)	68.1 ± 45.5
Rehabilitation center	39 (65%)
Home care physiotherapy	9 (15%)

Values are expressed as number of subjects (%), means ± SD or medians [first quartile; third
quartile]. Abbreviations: BMI, Body Mass Index; COPD, Chronic Obstructive Pulmonary disease;
ICU, Intensive Care Unit; £ARDS, Acute Respiratory Distress Syndrome, in accordance to the
Berlin definition criteria; CRP, C-Reactive Protein; WBC, White Blood Cell. *Data was unavailable
for n=1 patient.** Data was unavailable for n=6 patients.

Table 2. Characteristics of the study population at 12 months follow-up.

	<i>n</i> = 60
Respiratory symptoms	
Dyspnea	
mMRC 0	30 (50%)
mMRC ≥ 1	30 (50%)
Cough	9 (15%)
Pulmonary function tests	
VC (L)	3.7 (3.1-4.3)
VC (% predicted)	109 (95.8-120.5)
FEV ₁ (L)	3.03 (2.5-3.5)
FEV ₁ (% predicted)	106.3 (94.5-123.5)
FEV ₁ /VC (%)	81 (72.2-85)
TLC (L)	5.99 (5.1-6.6)
TLC (% predicted)	93 (85.2-103.5)
D _{LCO} cor (ml/min/mmHg)	23.8 (19.7-27.1)
D _{LCO} cor (% predicted)	99.1 (90.5-112.9)
KCO (ml/min/mmHg/L)	4.4 (9.9-4.8)
KCO (% predicted)	103 (94.3-114.9)
pO ₂ (mmHg)	82.2 ± 9.2
pCO ₂ (mmHg)	36.8 ± 3.9
Bicarbonate (mmol/L)	23.3 ± 2.1
Chest Computed tomography scan	
Normal	10 (16 %)
Reticulations	
1-25%	34 (57%)
26-50%	8 (13%)
>50%	0 (0.0%)
Ground-glass opacities	
1-25%	27 (45%)
26-50%	1 (1.7%)
>50%	1 (1.7%)
Bronchiectasis	
1-25%	33 (55%)
26-50%	2 (3.3%)
>50%	0 (0.0%)
Emphysema	

1-25%	5 (8.3%)
26-50%	3 (5.0%)
>50%	3 (5.0%)
Honeycombing	
1-25%	3 (5.0%)
>25%	0 (0.0%)

Data are shown as the number of subjects (%), means ± SD (standard deviation) or medians [first
quartile; third quartile]. Abbreviations: mMRC, modified Medical Research Council; FVC, Forced
Vital Capacity; FEV1, Forced Expiratory Volume at 1st second; TLC, Total Lung Capacity; D_{LCO}cor,
Diffusion Capacity of carbon monoxide; KCO, Carbon monoxide transfer coefficient; PcapO2,
capillary arterialized pO2; PcapCO2, capillary arterialized pCO2.

448

Table 3. Cardiopulmonary exercise test (CPET) results at 12 months follw-up (n=60).

Variables	Anaerobic threshold	Peak
Reasons for stopping		
Leg discomfort	-	33 (55%)
Breathing discomfort	-	22 (36.6%)
Both	-	3 (5%)
Other	-	2 (3.3%)
Performance		
Workload (W, % predicted)	65.8 (57.5-73.2)	103 (92.5-121.3)
V'O ₂ (L/min)	1.3 ± 0.3	1.9 ± 0.5
V'O ₂ (L/min, % predicted)	65 (57.1-70.9)	98.2 (87.2-106.2)
V'O ₂ (ml/min/kg)	14.2 ± 3.1	21.8 ± 5.2
V'O ₂ , (ml/min/kg, % predicted)	64.8 (57.2-70.9)	98.0 (87.2-106.3)
V'O ₂ /Watts (ml/min/watts)	15.3 (14-16.5)	14.3 (13.5-15.7)
MET	4.1 ± 0.9	6.2 ± 1.5
RER	0.9 ± 0.1	1.1 ± 0.1
Ventilation		
VT (L)	7.7 ± 0.4	2.2 ± 0.5
VT (% FVC)	46.2 ± 10.9	59.8 ± 8.2
VE (L/min)	39.7 ± 9.7	81.9 ± 22
RR (breaths/min)	24 ± 5	37 ± 6
Breathing reserve (%)	66.7 ± 8.7	32.6 ± 13.7
PetCO2 (mmHg)	39.6 ± 5.7*	34.3 ± 5.2*
Circulation		
HR (beats/min, % predicted)	78.2 ± 11.2	96.6 ± 12.7
Heart Rate reserve (%)	24.3 (12.8-29.9)	2.3 (0-15)
V'O2 pulse (ml/beat/min)	10.5 ± 2.6	12.9 ± 3.1
V'O ₂ pulse (% predicted)	84.6 ± 16.1	103.7 ± 19.9
$\Delta HR/\Delta V'O_2$	-	41.9 (33.6-48.7)
Δν'02/ΔWR	-	14.2 (13.5-15.7)
Gas exchange		
V'E/V'O ₂	31.7 ± 4.9	42.7 ± 6.6
V'E/V'CO ₂	33.5 (30-37)	37.5 (34-42)
V'E/V'CO ₂ slope	-	$37.2 \pm 6.7^*$
OUES (L/min)	-	1.8 (1.6-2.3)*
рH	$7.4 \pm 0.03^{*}$	7.3 ± 0.05*
pCapO₂ (mmHg)	82.3 (73.4-85.4)*	85.4 (72.4-87)*

pCapCO ₂ (mmHg)	38.2 ± 4.1*	$34.8 \pm 4.1^*$
P(A-a)O ₂ (mmHg)	26.4 (22.4-34.9)*	35.2 (31.2-44.8)*
V _D /V _T	0.27 (0.21-0.34)**	0.29 (0.25-0.35)**
Metabolic		
Lactatemia (mmol/L)	3.4 ± 1.1*	7.6 ± 2.2**

Data are shown as the number of subjects (%), means ± SD or medians [first quartile; third 451 quartile]. Abbreviations: V'O2, oxygen uptake; MET, metabolic equivalent; ; RER, Respiratory 452 Exchange Ratio; VT, tidal volume; FVC, Forced Vital Capacity; VE, minute ventilation; RR, 453 respiratory rate; PetCO2, end-tidal pressure of CO2; HR, heart rate; WR: Work Rate; V'E/V'O2 and 454 V'E/V'CO2, ventilatory equivalents for oxygen and carbon dioxide; OUES, Oxygen Uptake 455 456 Efficiency Slope; PcapO2, capillary arterialized pO2; PcapCO2, capillary arterialized pCO2; P(A-457 a)O2 Alveolar-arterial gradient for O2; VD, dead space. *Missing values for n=3 patients. **Missing values for n=1 patient. 458

459

- 461 Table 4. Multiple linear regression identifying factors associated with V'O2 peak
- 462 (ml/kg/min).

	p value	β coefficient	95% CI for β	Standard error of
				β
Intercept	<0.0001	53.60	44.07 to 63.13	4.75
Age (years)	< 0.001	-0.19	-0.23 to -0.08	0.05
Sexe	< 0.001	-4.36	-6.85 to -1.90	1.23
BMI	< 0.001	-0.42	-0.65 to -0.19	1.11
Length of ICU stay	0.01	-0.10	-0.18 to -0.02	0.04
(days)				
R ² 0.57				

Table 5. Comparison of patients with reduced and normal exercise capacity.

468

Variables	VO2 peak < 85%	VO2 peak ≥ 85%	p value
	(n=12)	(n=48)	
Patient's characteristics			
Age (years)	65.4 (59.8-72.3)	68.1 (58.1-71.8)	0.96
BMI (kg/m2)	33.4 ± 6.2	30.1 ± 4.5	0.04
Smoker or former smoker	8 (66.7%)	26 (54.2%)	0.52
ICU stay (days)	29.7 ± 13.1	19.1 ± 11.3	0.006
Ischemic heart disease	1 (8.3%)	4 (8.3%)	>0.99
COPD	1 (8.3%)	4 (8.3%)	>0.99
Asthma	2 (16.7%)	4 (8.3%)	0.59
Pulmonary embolism	3 (25%)	13 (27.1%)	0.88
Respiratory rehabilitation	9 (75%)	30 (62.5%)	0.41
Chest computed tomography			
scan #			
Emphysema	4 (33.3%)	7 (14.6%)	0.69
Reticulations	9 (75%)	33 (68.7%)	>0.99
Traction bronchiectasis	8 (66.7%)	27 (56.2%)	0.74
Honeycombing	0 (0.0%)	3 (6.2%)	>0.99
Ground-glass opacities	4 (33.3%)	25 (52.1%)	0.24
Pulmonary function tests			
FEV1 (% predicted)	97.4 ± 16.9	110.8 ± 19.7	0.03
FVC (% predicted)	97.5 ± 17.8	110.8 ± 16.9	0.01
TLC (%predicted)	87.7 ± 12.6	95.9 ± 14.3	0.07
DL _{co} cor (%predicted)	91.3 (65.6-98.1)	103 (92.3-114.2)	0.01
KCO (%predicted)	96.1 ± 29.9	104.8 ± 15.5	0.16
CPET at AT			
PetCO ₂ (mmHg)	39.3 ± 6.9 *	39.6 ± 5.5 **	0.87
Anaerobic threshold (%VO2	59.1 (49.1-65.2)	66.1 (58.1-73.2)	0.01
peak predicted)			
CPET at peak			
Performance			
Reasons for stopping			
exercise			
Leg discomfort	8 (66.7%)	25 (52.1%)	0.51
Dyspnea discomfort	4 (33.3%)	18 (37.5%)	>0.99
Both	0 (0.0%)	3 (6.2%)	>0.99
Others	0 (0.0%)	2 (4.2%)	>0.99

Effort duration (sec)	547.6 ± 128.9	585.7 ± 86.2	0.21
Workload (% predicted)	85.7 (80.1-96.9)	107.2 (98.4-124.5)	<0.0001
V'O ₂ (L/min)	1.6 ± 0.5	2.0 ± 0.5	0.03
V'O ₂ (L/min, % predicted)	82.1 (73.7-83.7)	101.9 (94.6-107.7)	<0.0001
V'O ₂ (ml/min/kg)	16.9 ± 4.2	23.0 ± 4.7	0.0001
V'O ₂ (ml/min/kg, %	82 (73.9-83.9)	101.6 (94.8-107.5)	<0.0001
predicted)			
MET	4.8 ± 1.2	6.6 ± 1.3	0.0001
Ventilation			
VE (L/min)	74.9 ± 21.9	83.6 ± 21.9	0.22
RER	1.1 ± 0.1	1.1 ± 0.1	0.14
Breathing reserve (%)	34.4 ± 15.4	32.1 ± 13.4	0.61
PetCO ₂ (mmHg)	34.0 ± 5.3 *	34.3 ± 5.3 **	0.86
Circulation			
HR (beats/min,	94.3 ± 11.9	97.2 ± 12.9	0.49
%predicted)			
Heart rate reserve (%)	4.1 (0-18.6)	1.6 (0-14.7)	0.68
VO ₂ pulse (%predicted)	83.9 ± 11.3	108.7 ± 18.6	<0.0001
Δ HR/ Δ V'O ₂	47.5 (36.6-51.2)	39.9 (32.2-47.5)	0.08
$\Delta V'O_2/\Delta WR$	13.9 (12.9-16.1)	14.3 (13.6-15.3)	0.54
Gas exchange			
VE/VO ₂ ratio	45.7 ± 7.9	42.1 ± 6.1	0.08
OUES (L/min)	1.6 (1.5-2.0)	1.9 (1.7-2.3)	0.14
VE/VCO ₂ ratio	39.5 (33.5-47.0)	37.5 (34-41)	0.36
VE/VCO ₂ slope	37.2 ± 7.6*	37.2 ± 6.6*	0.99
VD/Vt	0.35 (0.28-0.40)*	0.29 (0.25-0.34)**	0.06
рН	7.3 ± 0.04**	7.3 ± 0.05	0.36
pCapO ₂ (mmHg)	78.2 (54.2-82.1)*	83.8 (76.8-87.1)**	0.05
pCapCO ₂ (mmHg)	35.9 (33.4-39.4)**	34.7 (30.7-37.3)	0.14
P(A-a) (mmHg)	43.49 (29.7-60.5)*	34.7 (31.7-43.9)**	0.23
Metabolic			
Lactatemia (mmol/L)	7.2 ± 2.4*	7.7 ± 2.2	0.54

Data are shown as the number of subjects (%), means ± SD or medians [first quartile; third quartile], Student's t- or Mann–Whitney tests were computed to assess statistical differences for normal or non-normal quantitative. Fisher's exact test was used for analysis of contingency tables. Abbreviations: BMI, Body Mass Index; ICU, Intensive Care Unit; COPD: Chronic Obstructive Pulmonary Disease; FEV1, Forced Expiratory Volume at 1st second; FVC, Forced Vital Capacity; TLC, total lung capacity; DLCOcor, lung transfer for carbon monoxide; KCO, carbon monoxide

transfer coefficient; V'O2, oxygen uptake; MET, metabolic equivalent; RR, respiratory rate; V'E,

- 476 minute ventilation; RER, respiratory exchange ratio; PetCO2, end-tidal pressure of CO2; HR, heart
- 477 rate; WR: Work Rate; V'CO2, carbon dioxide production; OUES, oxygen uptake efficiency slope;
- 478 V'E/V'O2 and V'E/V'CO2, ventilatory equivalents for oxygen and carbon dioxide; VD, dead space;
- 479 Vt, tidal volume; PcapO2, capillary arterialized pO2; PcapCO2, capillary arterialized pCO2; P(A-
- 480 a)O2; Alveolar-arterial gradient for O2. * Missing values for n=2 patients. **Missing values for n=1
- 481 patient.
- 482

- 483 Table 6. Results of univariate analysis to identify factors associated with peak VD/Vt in
- 484 patients with normal exercise capacity (n=48).

	r²	p value
Patient's characteristics		
Age (years)	0.13	0.01
Sexe	0.07	0.07
BMI (kg/m2)	0.03	0.2
Length of ICU stay (days)	0.24	0.10
Pulmonary embolism	0.01	0.3
CRP (mg/ml)	0.004	0.6
Fibrinogen (g/L)	0.009	0.5
D-Dimers (ng/ml)	0.12	0.02
Creatinine (mg/dl)	0.07	0.07
Total WBC count (10 ⁹ /L)	0.03	0.2
Pulmonary function tests		
FEV1 (% predicted)	0.08	0.05
FEV1 (L)	0.02	0.3
VC (% predicted)	0.03	0.2
VC (L)	0.002	0.7
DL _{co} cor (%predicted)	0.15	0.01
DL _{co} cor (ml/min/mmHg)	0.06	0.09
CPET at AT		
PetCO ₂	-0.53	0.0001
%VO2 peak predicted	-0.11	0.46
CPET at peak		
V'O ₂ peak, ml/kg/min %predicted	-0.17	0.25
V'O ₂ peak, ml/kg/min		
PetCO ₂	-0.43	0.003
V'E/VO ₂ ratio	0.48	0.0006
V'E/V'CO ₂ ratio	0.58	<0.0001
V'E/V'CO2 slope	0.53	0.0001
V'O ₂ pulse (%predicted)	0.1	0.52
pO ₂ (mmHg)	0.13	0.01
pCO ₂ (mmHg)	0.004	0.8
P(A-a) (mmHg)	0.46	0.01

Abbreviations: BMI, Body Mass Index; ICU, Intensive Care Unit; CRP, C-Reactive Protein; WBC,

486 White Blood Cell; FEV1, Forced Expiratory Volume at 1st second; FVC, Forced Vital Capacity;

487 TLC, total lung capacity; D_{LCO}cor, lung transfer for carbon monoxide; KCO, carbon monoxide

- 488 transfer coefficient; PetCO2, end-tidal pressure of CO₂; RER, respiratory exchange ratio; V'O₂,
- 489 oxygen uptake; V'E/V'O₂ and V'E/V'CO₂, ventilatory equivalents for oxygen and carbon dioxide;
- 490 HR, heart rate; PcapO₂, capillary arterialized pO2; PcapCO₂, capillary arterialized pCO₂;P(A-a)O₂
- 491 Alveolar-arterial O₂ gradient.

493 **Figure Legends**

- 495 Figure 1. Scatterplot depicting the relationship of peak oxygen uptake (V'O₂) with a) 6-
- 496 minute walk test (MWT) distance b) length of ICU stay (days).
- 497 **Figure 2.** Evolution of ventilatory efficiency parameters from rest to peak in patients with
- 498 normal exercise capacity (n=48). a) VD/Vt b) alveolar-arterial gradient c) PetCO
- 499 **Suppl Figure**. Flowchart of the prospective cohort study.

500 References

Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. Nat Rev Microbiol 2022;
 20(5): 270-84.

503 2. Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19: 504 a longitudinal cohort study. Lancet 2021; 398(10302): 747-58.

Sos 3. Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent Symptoms in
 Patients After Acute COVID-19. JAMA 2020; 324(6): 603-5.

4. American Thoracic S, American College of Chest P. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167(2): 211-77.

509 5. Rinaldo RF, Mondoni M, Parazzini EM, et al. Deconditioning as main mechanism of 510 impaired exercise response in COVID-19 survivors. Eur Respir J 2021; 58(2).

511 6. Skjorten I, Ankerstjerne OAW, Trebinjac D, et al. Cardiopulmonary exercise 512 capacity and limitations 3 months after COVID-19 hospitalisation. Eur Respir J 2021; 513 58(2).

7. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for
spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J
2012; 40(6): 1324-43.

Stanojevic S, Graham BL, Cooper BG, et al. Official ERS technical standards:
 Global Lung Function Initiative reference values for the carbon monoxide transfer factor for
 Caucasians. Eur Respir J 2017; 50(3).

520 9. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory
521 symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959;
522 2(5147): 257-66.

10. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J. Fleischner
Society: glossary of terms for thoracic imaging. Radiology 2008; 246(3): 697-722.

525 11. Force ERST, Palange P, Ward SA, et al. Recommendations on the use of exercise
526 testing in clinical practice. Eur Respir J 2007; 29(1): 185-209.

527 12. Borg G. Ratings of perceived exertion and heart rates during short-term cycle 528 exercise and their use in a new cycling strength test. Int J Sports Med 1982; 3(3): 153-8.

13. Hansen JE, Sue DY, Wasserman K. Predicted values for clinical exercise testing.
Am Rev Respir Dis 1984; 129(2 Pt 2): S49-55.

531 14. Force ADT, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome:
532 the Berlin Definition. JAMA 2012; 307(23): 2526-33.

533 15. Sun XG, Hansen JE, Garatachea N, Storer TW, Wasserman K. Ventilatory
 534 efficiency during exercise in healthy subjects. Am J Respir Crit Care Med 2002; 166(11):

535 **1443-8**.

16. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics,
Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the
New York City Area. JAMA 2020; 323(20): 2052-9.

17. Clavario P, De Marzo V, Lotti R, et al. Cardiopulmonary exercise testing in COVID19 patients at 3 months follow-up. Int J Cardiol 2021; 340: 113-8.

18. Ribeiro Baptista B, d'Humieres T, Schlemmer F, et al. Identification of factors
impairing exercise capacity after severe COVID-19 pulmonary infection: a 3-month followup of prospective COVulnerability cohort. Respir Res 2022; 23(1): 68.

Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the
 acute respiratory distress syndrome. N Engl J Med 2003; 348(8): 683-93.

Ahmed H, Patel K, Greenwood DC, et al. Long-term clinical outcomes in survivors
of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus
outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. J
Rehabil Med 2020; 52(5): jrm00063.

Motiejunaite J, Balagny P, Arnoult F, et al. Hyperventilation: A Possible Explanation
for Long-Lasting Exercise Intolerance in Mild COVID-19 Survivors? Front Physiol 2020;
11: 614590.

Debeaumont D, Boujibar F, Ferrand-Devouge E, et al. Cardiopulmonary Exercise
Testing to Assess Persistent Symptoms at 6 Months in People With COVID-19 Who
Survived Hospitalization: A Pilot Study. Phys Ther 2021; 101(6).

556 23. Naeije R, Caravita S. Phenotyping long COVID. Eur Respir J 2021; 58(2).

557 24. Baratto C, Caravita S, Faini A, et al. Impact of COVID-19 on exercise
558 pathophysiology: a combined cardiopulmonary and echocardiographic exercise study. J
559 Appl Physiol (1985) 2021; 130(5): 1470-8.

560 25. Taverne J, Salvator H, Leboulch C, et al. High incidence of hyperventilation 561 syndrome after COVID-19. J Thorac Dis 2021; 13(6): 3918-22.

Mancini DM, Brunjes DL, Lala A, Trivieri MG, Contreras JP, Natelson BH. Use of
Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post-Coronavirus
Disease. JACC Heart Fail 2021; 9(12): 927-37.

565 27. Fresard I, Genecand L, Altarelli M, et al. Dysfunctional breathing diagnosed by 566 cardiopulmonary exercise testing in 'long COVID' patients with persistent dyspnoea. BMJ 567 Open Respir Res 2022; 9(1).

28. Ambrosino P, Parrella P, Formisano R, et al. Cardiopulmonary Exercise
 Performance and Endothelial Function in Convalescent COVID-19 Patients. J Clin Med

570 2022; 11(5).

29. Robertson HT, Pellegrino R, Pini D, et al. Exercise response after rapid intravenous
infusion of saline in healthy humans. J Appl Physiol (1985) 2004; 97(2): 697-703.

573 30. Dantzker DR, D'Alonzo GE. Pulmonary gas exchange and exercise performance in 574 pulmonary hypertension. Chest 1985; 88(4 Suppl): 255S-7S.

- 575 31. Gille T, Laveneziana P. Cardiopulmonary exercise testing in interstitial lung 576 diseases and the value of ventilatory efficiency. Eur Respir Rev 2021; 30(162).
- 577 32. Weatherald J, Philipenko B, Montani D, Laveneziana P. Ventilatory efficiency in 578 pulmonary vascular diseases. Eur Respir Rev 2021; 30(161).
- 579 33. Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future 580 prospects. Blood 2009; 113(13): 2878-87.
- 34. Bonaventura A, Vecchie A, Dagna L, et al. Endothelial dysfunction and
 immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol 2021;
 21(5): 319-29.
- 584 35. Rovas A, Osiaevi I, Buscher K, et al. Microvascular dysfunction in COVID-19: the 585 MYSTIC study. Angiogenesis 2021; 24(1): 145-57.
- 36. Gamberini L, Mazzoli CA, Prediletto I, et al. Health-related quality of life profiles,
- trajectories, persistent symptoms and pulmonary function one year after ICU discharge in
- invasively ventilated COVID-19 patients, a prospective follow-up study. Respir Med 2021;189: 106665.

a



b



Peak VO₂ (mL /kg/min)

medRxiv preprint doi: https://doi.org/10.1101/2022.09.12.22279779; this version posted September 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



